-+ 0.00%
-+ 0.00%
-+ 0.00%

SHATTUCK LABS ANNOUNCES PHASE 2 CLINICAL TRIAL OF SL-325 IN HIDRADENITIS SUPPURATIVA AND APPOINTMENT OF SHOBA RAVICHANDRAN, M.D., AS SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT

Reuters·10/01/2026 11:02:47